Polylite Taiwan Co., Ltd. (1813) AI Stock Analysis

Polylite Taiwan Co., Ltd.

(TPEx:1813)

Select Model

Rating:43Neutral

Price Target:TWD 10.00▼(-4.31% Downside)

Action:initiatedcoverage

Date:11/09/26

Weak financial performance due to ongoing profitability challenges and declining revenues is the primary factor lowering the score, followed by unfavorable technical indicators showing a prevailing downtrend.

Positive Factors

Moderate LeverageModerate leverage gives Polylite a stronger financial foundation than a highly indebted peer and preserves some flexibility to manage cyclical demand. Debt levels are not extreme, reducing the risk that interest or refinancing needs will overwhelm operations during the earnings downturn.

Negative Factors

Severe Revenue DeclineThe sharp two-year top-line deterioration indicates substantial pressure on demand or pricing and materially reduces the scale of the business. Unless revenue stabilizes, lower volume will make fixed costs harder to absorb and constrain the company’s ability to rebuild sustainable earnings.

Polylite Taiwan Co., Ltd. (1813) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 478.01M
Dividend Yield: ―
Average Volume (3M): 19.77K
Price to Earnings (P/E): 61.1
Beta (1Y): 0.23
Revenue Growth: -6.91%
EPS Growth: ―
Country: TW
Employees: 149
Sector: General
Sector Strength: 55
Industry: Semiconductors

Polylite Taiwan Co., Ltd. Business Overview & Revenue Model

Company Description

Polylite Taiwan Co., Ltd. is an international enterprise engaged in the fabrication, refinement, worldwide trade, and retail of a diverse selection of optical lenses, precision optical devices, and medical instruments. A key part of its product line...

Polylite Taiwan Co., Ltd. Financial Statement Overview

Summary

Revenue decline and negative profitability metrics significantly impact the score, though solid cash flows and moderate balance sheet leverage offer some offset.

Income Statement

18Very Negative

Balance Sheet

42Neutral

Cash Flow

68Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	287.69M	304.32M	309.91M	360.45M	362.05M	451.13M
Gross Profit	-47.72M	-52.32M	-59.80M	-3.93M	-22.26M	19.58M
EBITDA	-48.33M	-1.81M	-54.00M	-11.38M	11.54M	45.52M
Net Income	7.50M	-47.94M	-29.30M	11.20M	6.71M	-13.13M
Balance Sheet
Total Assets	968.25M	931.76M	1.01B	1.05B	1.14B	1.26B
Cash, Cash Equivalents and Short-Term Investments	146.40M	138.21M	119.04M	150.27M	210.44M	305.97M
Total Debt	238.04M	217.53M	241.96M	204.99M	251.25M	323.77M
Total Liabilities	304.44M	270.75M	302.59M	276.56M	315.79M	426.21M
Stockholders Equity	693.34M	684.54M	723.73M	774.95M	811.94M	813.72M
Cash Flow
Free Cash Flow	61.93M	36.53M	30.39M	36.75M	16.05M	60.11M
Operating Cash Flow	67.64M	46.81M	35.20M	46.22M	31.93M	78.68M
Investing Cash Flow	-16.24M	-10.05M	-67.63M	-9.11M	-14.79M	-19.50M
Financing Cash Flow	-12.73M	-18.84M	13.48M	-97.52M	-99.45M	29.27M

Polylite Taiwan Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1813 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:1813	43Neutral	TWD 478.01M	61.08	―	―	-6.91%	―

* General Sector Average

Performance Comparison

TW:1813 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1813	Polylite Taiwan Co., Ltd.	10.45	-2.75	-20.83%
TW:4115	Sunder Biomedical Tech. Co., Ltd.	6.97	-1.43	-17.02%
TW:4170	Vectorite Biomedical, Inc.	11.00	-2.60	-19.12%
TW:6660	HMD Biomedical, Inc.	12.70	-11.05	-46.53%
TW:6999	Han Biomedical, Inc.	24.45	-6.02	-19.75%
TW:7726	CARILEX MEDICAL INC.	32.15	-3.95	-10.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Polylite Taiwan Co., Ltd. AI Stock Analysis